Biogen Idec Inc (BIIB.O)
203.80USD
19 Jun 2013
$-7.00 (-3.32%)
$210.80
$210.47
$211.26
$203.59
1,213,582
1,494,928
$242.64
$134.00
BIIB.O
About
Overall
| Beta: | 0.88 |
| Market Cap (Mil.): | $50,038.61 |
| Shares Outstanding (Mil.): | 237.37 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.48 | 40.13 | 30.65 |
| EPS (TTM): | 6.30 | -- | -- |
| ROI: | 18.16 | 2.36 | 18.83 |
| ROE: | 22.05 | 3.58 | 19.74 |
Divisive Elan boss Martin faces ownership showdown
DUBLIN/NEW YORK - When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the troubled company and sell it.
Biogen delays MS drug's EU launch to secure market exclusivity
May 30 - Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer period.
Biogen profit beats estimates, raises 2013 forecast
- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.
UPDATE 3-Biogen profit beats estimates, raises 2013 forecast
April 25 - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.
BRIEF-Biogen sees Tecfidera becoming leading oral drug MS drug
April 25 - Biogen Idec Inc : * Says believes tecfidera will become leading oral drug in ms market
Biogen profit beats estimates, raises 2013 forecast
- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.
Biogen profit beats estimates, raises 2013 forecast
- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.
Biogen profit beats estimates, helped by lower taxes
- Biogen Idec Inc reported stronger-than-expected quarterly earnings, helped by unusually low taxes and sales growth of its treatments for multiple sclerosis.
Biogen profit beats estimates, helped by lower taxes
April 25 - Biogen Idec Inc reported stronger-than-expected quarterly earnings, helped by unusually low taxes and sales growth of its treatments for multiple sclerosis.
Elan completes sale of Tysabri stake to Biogen
DUBLIN - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend on acquisitions and stave off an approach for the company.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF67.15 | 0.00 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 14,220.00₪ | +100.00 |
| Sanofi SA (SASY.PA) | €80.79 | -0.76 |
| Pfizer Inc. (PFE.N) | $29.10 | -0.30 |
| Genmab A/S (GEN.CO) | kr.184.10 | -4.70 |
| GlaxoSmithKline plc (GSK.L) | 1,665.00p | -11.00 |
| Johnson & Johnson (JNJ.N) | $84.86 | -1.50 |
| Abbott Laboratories (ABT.N) | $36.21 | -1.30 |
| Amgen, Inc. (AMGN.OQ) | $99.18 | -2.32 |
| UCB SA (UCB.BR) | €39.47 | -0.14 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
